Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALRLong36 vaccine in CALR-mutant myeloproliferative neoplasms
NCT03566446Phase 1Completed
- Start
- Jun 2018
- Primary completion
- Feb 2020
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of mutant-calreticulin peptide vaccine in essential thrombocythemia (ET), myelofibrosis (MF) and Myeloproliferative Neoplasm (MPN). Started Jun 2018; status: completed.
02
Drugs
mutant-calreticulin peptide vaccine
03
Conditions
essential thrombocythemia (ET)myelofibrosis (MF)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT03566446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03566446.